Fresenius has announced the completion of its move to acquire the worldwide peritoneal dialysis (PD) business unit of fellow healthcare company Gambro.
The deal, which was originally agreed in September 2010, has been finalised following the obtainment of regulatory approval from the majority of the relevant antitrust authorities.
Both companies are now awaiting a final decision from the regulatory body in Serbia, which has issued only a preliminary approval thus far.
On announcing the transaction earlier this year, Fresenius explained that the acquisition will add around $60 million (38.9 million pounds) to its annual revenue.
It will also allow the company to expand its presence in the home dialysis market and the European and Asia-Pacific territories, which are key focus areas for Gambro.
Ben Lipps, chief executive officer of Fresenius Medical Care, said: "Promoting our growth in home therapies, of which PD is a key element, has been a defined path in our overall growth strategy."See all the latest jobs in Medical Devices